Search

In this study, we estimate atmospheric turbulence in the free atmosphere in terms of the Thorpe scale (LT) and eddy dissipation rate (ε) using U.S. high vertical‐resolution radiosonde data over 4 years (September 2012 to August 2016) at 68 operational stations. In addition, same calculations are conducted for 12 years (October 2005 to September 2017) at four stations among the 68 stations. These high vertical‐resolution radiosonde data have a vertical resolution of approximately 5 m and extend to an altitude of approximately 33 km, and thus, turbulence can be retrieved in the entire troposphere and lower stratosphere. There are thicker and stronger turbulent layers in the troposphere than in the stratosphere, with mean ε values of 1.84 × 10−4 and 1.37 × 10−4 m2/s3 in the troposphere and stratosphere, respectively. The vertical structure of ε exhibits strong seasonal variations, especially in the upper troposphere and lower stratosphere, with the largest ε values in summer and the smallest in winter. In the horizontal distribution of ε, large ε is seen mainly above the mountainous region in the troposphere, but this pattern is not seen in the stratosphere. Although ε is estimated by the square of LT multiplied by the cube of the Brunt‐Väisälä frequency (N), the regions of large ε are matched with large LT regions where N is relatively small. For the time series of ε near the tropopause for 12 years at four stations, an annual variation is prominent at all stations without significant interannual variations. There is, however, a slightly increasing trend of ε at two stations. Key Points: Turbulence parameters are estimated in the free atmosphere using Thorpe analysis and high vertical‐resolution radiosonde data in the United StatesCharacteristics of vertical, statistical, and horizontal distributions and long‐term variability of turbulence parameters are examined [ABSTRACT FROM AUTHOR]

A descriptive case study was performed on 75 patients with NF1 (neurofibromatosis type 1) from the CNNF (Brazil) database. Serum IgE levels were determined using the IgE radioimmunosorbent test, with the reference values of 75–502 IU mL−1. The patients were divided into groups, with 25 patients presenting plexiform neurofibromas, 25 presenting neurofibromas and 25 presenting no neurofibromas. The purposes of this study were to determine the serum IgE levels of patients with NF1 presenting plexiform neurofibromas, neurofibromas and no neurofibromas, as well as to determine possible correlations between serum IgE levels and the size of the plexiform neurofibromas and neurofibromas presented by these patients. Elevated serum IgE levels were observed in all the patient groups. We did not observe a correlation between IgE levels and age in these patients; however, we did observe correlations between IgE levels and neurofibroma and plexiform neurofibroma size. We suggest further studies to confirm these results and to investigate in greater depth the possible role of IgE in the development and growth of neurofibromas and plexiform neurofibromas in NF1. [ABSTRACT FROM AUTHOR]

Antioxidants may have a role in the prevention of atherosclerosis. In the present trial, we investigated the antioxidant properties of Palm Vitee, a γ-tocotrienol-, and α-tocopherol enriched fraction of palm oil, in patients with carotid atherosclerosis. Serum lipids, fatty acid peroxides, platelet aggregation, and carotid artery stenosis were measured over an 18-month period in fifty patients with cerebrovascular disease. Change in stenosis was measured with duplex ultrasonography. Ultrasound scans were done at six months, twelve months, and yearly thereafter. Bilateral duplex ultrasonography revealed apparent carotid atherosclerotic regression in seven and progression in two of the 25 tocotrienol patients, while none of the control group exhibited regression and ten of 25 showed progression ( P<0.002). Serum thiobarbituric acid reactive substances, an ex vivo indicator of maximal platelet peroxidation, decreased in the treatment group from 1.08±0.70 to 0.80±0.55 μM/L ( P<0.05) after 12 mon, and in the placebo group, they increased nonsignificantly from 0.99±0.80 to 1.26±0.54 μM/L. Both tocotrienol and placebo groups displayed significantly attenuated collagen-induced platelet aggregation responses ( P<0.05) as compared with entry values. Serum total cholesterol, low density lipoprotein cholesterol, and triglyceride values remained unchanged in both groups, as did the plasma high density lipoprotein cholesterol values. These findings suggest that antioxidants, such as tocotrienols, may influence the course of carotid atherosclerosis. [ABSTRACT FROM AUTHOR]

Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved., (© 2012 John Wiley & Sons A/S.)